Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a phase 1/2 multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of sacituzumab tirumotecan (MK-2870) plus paclitaxel versus ramucirumab plus paclitaxel, and HER3-DXD plus ramucirumab versus ramucirumab plus paclitaxel for the treatment of participants with advanced or metastatic gastric adenocarcinoma, gastroesophageal junction (GEJ) adenocarcinoma, or esophageal adenocarcinoma who have failed 1 prior line of therapy. This is an estimation study, and no formal hypothesis testing will be performed.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Zdiagnozowano raka żołądka, przełyku lub połączenia przełykowo-żołądkowego, który jest w zaawansowanym stadium lub rozprzestrzenił się.
- •Pacjent otrzymał już jedną linię leczenia antynowotworowego, ale rak nadal postępuje.
- •Badania potwierdziły, że rak nie wytwarza białka HER2.
- •Wymagane jest pobranie próbki guza do badań, jeśli nie była wcześniej naświetlana.
- •Złe samopoczucie związane z wcześniejszym leczeniem jest łagodne (nie gorsze niż w pierwszym stopniu zaawansowania) lub ustąpiło.
- •Pacjent jest w ogólnie dobrym stanie zdrowia (ocena według skali ECOG 0 lub 1).
- •Przewidywana długość życia pacjenta wynosi co najmniej 3 miesiące.
✗ Disqualifies
- •Zdiagnozowano inny typ raka niż gruczolak, np. rak płaskonabłonkowy.
- •Pacjent stracił ponad 20% masy ciała w ciągu 3 miesięcy przed rozpoczęciem badania.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 24, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (47)
University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 8927)
Tucson, United States
UCLA Hematology/Oncology - Santa Monica ( Site 8905)
Los Angeles, United States
Norton Cancer Institute - Downtown ( Site 8900)
Louisville, United States
The Cancer and Hematology Centers ( Site 8912)
Grand Rapids, United States
Hematology-Oncology Associates of Central NY, P.C. ( Site 8925)
East Syracuse, United States
Columbia University Irving Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical ( Site 8907)
New York, United States
UPMC Hillman Cancer Center-UPMC ( Site 8904)
Pittsburgh, United States
University of Texas MD Anderson Cancer Center ( Site 8920)
Houston, United States
Liga Norte Riograndense Contra o Câncer ( Site 8303)
Natal, Brazil
Hospital Nossa Senhora da Conceição ( Site 8301)
Porto Alegre, Brazil
IBCC - Instituto Brasileiro de Controle do Câncer ( Site 8304)
São Paulo, Brazil
ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 8300)
São Paulo, Brazil
Clínica Puerto Montt ( Site 8409)
Port Montt, Chile
Centro de Investigación del Maule ( Site 8408)
Talca, Chile
FALP-UIDO ( Site 8400)
Santiago, Chile
Centro de Oncología de Precisión-Oncology ( Site 8404)
Santiago, Chile
Clínica UC San Carlos de Apoquindo ( Site 8405)
Santiago, Chile
Bradfordhill-Clinical Area ( Site 8401)
Santiago, Chile
Bradford Hill Norte ( Site 8407)
Antofagasta, Chile
Beijing Cancer hospital-Digestive Oncology ( Site 7500)
Beijing, China
The 900th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army ( Site 7501)
Fuzhou, China
The First Affiliated hospital of Xiamen University ( Site 7503)
Xiamen, China
Henan Cancer Hospital ( Site 7504)
Zhengzhou, China
The First Affiliated Hospital of Nanchang University ( Site 7514)
Nanchang, China
Fudan University Shanghai Cancer Center ( Site 7513)
Shanghai, China
Xinjiang Medical University Cancer Hospital - Urumqi ( Site 7506)
Ürümqi, China
Sir Run Run Shaw Hospital of Zhejiang University School of Medicine ( Site 7510)
Hangzhou, China
Centre Hospitalier Régional Universitaire de Brest - Hôpital-Institut de cancérologie et hématologi ( Site 7104)
Brest, France
CIC. ( Site 7100)
Lille, France
Pitie Salpetriere University Hospital-Hepato-Gastro-Enterology ( Site 7102)
Paris, France
NCT-Department of Medical Oncology ( Site 8809)
Heidelberg, Germany
Universitaetsklinikum Duesseldorf-Gastroenterology, Hepatology and Infectiology ( Site 8802)
Düsseldorf, Germany
Universitaetsklinikum Carl Gustav Carus Dresden-Medical Dept I - Medical Oncology ( Site 8806)
Dresden, Germany
Facharztzentrum Eppendorf-Facharztzentrum Eppendorf ( Site 8807)
Hamburg, Germany
IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"-Oncologia Medica ( Site 7207)
Meldola, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 7200)
Milan, Italy
Azienda Ospedaliero Universitaria Pisana ( Site 7206)
Pisa, Italy
Ospedale San Raffaele-Oncologia Medica ( Site 7202)
Milan, Italy
Oslo universitetssykehus, Radiumhospitalet ( Site 8501)
Oslo, Norway
Asan Medical Center-Department of Oncology ( Site 7901)
Seoul, South Korea
Samsung Medical Center-Division of Hematology/Oncology ( Site 7900)
Seoul, South Korea
Hôpitaux Universitaires de Genève (HUG) ( Site 8701)
Geneva, Switzerland
Kantonsspital Graubünden-Medizin ( Site 8700)
Chur, Switzerland
China Medical University Hospital ( Site 8007)
Taichung, Taiwan
National Cheng Kung University Hospital ( Site 8001)
Tainan, Taiwan
National Taiwan University Hospital-Oncology ( Site 8000)
Taipei, Taiwan
Taipei Veterans General Hospital ( Site 8005)
Taipei, Taiwan
Trial contact
Toll Free Number
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/7/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.